# HTScience

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/htscience

- Industry: Biotechnology
- Headquarters: Guangzhou, China
- Website: www.htscience.com
- Latest round: Series A (Aug 30, 2023)
- Investors on record: 3

## About

Established in 2019 and based in Guangzhou, China, Guangzhou Huateng Biomedical Technology Co., Ltd., dba HTScience, is a pre-clinical and life science research and development service provider. The company has subsidiaries in Foshan and Shenzhen, with a laboratory area of over 10,000 square meters, also has a core team of scientists from universities and research and development institutions such as South China University of Technology and National University of Singapore. At the same time, the company has provided technical services for Baiyunshan Pharmaceutical, Microchip Bio and other institutions and manufacturers, and has successfully submitted several IND applications to USFDA and CFDA, and entered clinical trials. In January 2026, HTScience closed Series A+ funding from new investor Guangzhou GuangDian PingYun Industry Investment.
The company specializes in pre-clinical research and development services for pharmaceuticals, medical devices, gene and cell therapies. It uses technologies such as gene editing, surgical modeling and chemical diet induction to construct animal models of human diseases, which can simulate the development of clinical diseases and provide a tool platform for biopharmaceutical research and development.
HTScience generates revenue by providing R&D services such as high-throughput disease target screening, gene-edited cell line construction, disease animal model construction, pharmacology, drug metabolism and safety evaluation (Non-GLP).
The company will use the funding in January 2026 to enhance the company's technical capabilities and service system in the fields of preclinical drug development and life science R&D outsourcing services.

## Funding rounds

- Series A, Aug 30, 2023 — Wanlian Tianze, Yanghe Biomedicine Industry Investment
- Series A, Sep 5, 2022 — Zhongke Yuechuang Investment

## Investors

- Zhongke Yuechuang Investment (https://capitalatlas.ai/funds/zhongke-yuechuang-investment) — Series A
- Wanlian Tianze (https://capitalatlas.ai/funds/wanlian-tianze) — Series A
- Yanghe Biomedicine Industry Investment (https://capitalatlas.ai/funds/yanghe-biomedicine-industry-investment) — Series A